Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
نویسندگان
چکیده
منابع مشابه
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
1Phase I Early Clinical Trials Unit, Department of Oncology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium 2Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain 3Early Development Drugs Unit, Medical Oncology Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile 4Department of Oncology, Universita degli Studi di Palermo, Palermo...
متن کاملStatins: have we found the Holy Grail?
In coronary artery disease, cardiovascular risk factors are the main targets for primary and secondary prevention. Statins prevent cardiovascular events in patients at risk. However, despite the proven efficacy and safety of statins, relevant side effects exist and should be considered when treating patients.
متن کاملThe Missing Memristor has Not been Found
In 1971, not only the theoretical and by definition already existing 'ideal memristor' concept was introduced, but a real memristor device was suggested on grounds of the already known real inductors. The latter is a scientifically significant hypothesis grounded in fundamental symmetries of basic physics, here electro-magnetism. 2008 claimed the discovery of the "missing memristor." Controvers...
متن کاملIn search of the holy grail: lung cancer biomarkers.
A central paradigm in the care of patients with lung cancer is to offer surgery with curative intent (and hopefully outcome) to as many patients as possible while performing as few unnecessary surgeries as possible. " Unnecessary " surgery must be defined first as surgery in patients with advanced stage disease, in whom (at this time) surgery offers no benefit over chemoradiation therapy. Exact...
متن کاملSelective allodepletion: have we finally found the holy grail?
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for patients with hematologic malignancies and nonmalignant disorders of hematopoiesis. Outcomes of allogeneic HSCT have improved steadily over the decades [1]. However, significant challenges remain. One of these challenges is the so-called Holy Grail of stem cell transplantation immunology: to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ESMO Open
سال: 2017
ISSN: 2059-7029
DOI: 10.1136/esmoopen-2017-000162